BridgeBio Pharma’s Pipeline Expansion Continues As Existing Portfolio’s Milestones Approach
The company already has more than 20 subsidiaries developing treatments for monogenic diseases and genetically defined cancers, but its deal-making pace has not slowed.
You may also be interested in...
BridgeBio’s Hub-And-Spoke Model: An Interview With Cameron Turtle
Since raising $135m in 2017 to address rare, monogenic diseases, BridgeBio has launched or purchased 17 companies and built a pipeline of 30-plus candidates. Scrip checked in as the company nears commercialization.
Tech Transfer Roundup: NCI Licenses Leukemia, Brain Cancer Candidates To Vor, Connectyx
NIH’s National Cancer Institute licensed two experimental cancer therapies in the past month to biopharma firms, leading a heavy slate of cancer-focused tech transfer deal-making.
Asia Deal Watch: Perceptive Launches LianBio With “China-Centric” Strategy
Headquartered in both China and US, the new firm will help partners bring drugs to China and other Asian markets. Novavax licenses COVID-19 vaccine in Japan to Takeda, following previous week’s deal for the vaccine in India.